UsAgainstAlzheimer’s A-LIST® is an Online Community
where people with Alzheimer’s disease and other dementias, mild cognitive impairment, and family caregivers come together to research the experience of living with this disease and caring for a loved one. We call it the science of us.
Join the 8,206 A-LIST members who are letting the world know what matters most to us.
How the A-LIST Works:
Online surveys: Twice a month you will receive an email from A-LIST Founder Meryl Comer inviting you to answer a short survey.
Surveys ask about the issues we care about: Past survey topics include challenges for caregivers; dementia symptoms, such as agitation; managing the COVID-19 pandemic; and traveling with dementia.
We use anonymous survey results to make life better for our community: We make sure policy makers, researchers, health care providers, drug developers, insurers, and others who serve our community understand and consider our insights and preferences.
Get started! CLICK HERE to add your name, then check “I Agree” to sign our consent form that explains the A-LIST study. Then take our first online survey: the Pulse of the Community.
"There is strength in the number of caregivers willing to devote their daily lives to improving the lives of their loved ones suffering from Alzheimer’s. The A-LIST nurtures that strength by bringing us together to facilitate a path to a cure, and centering on the needs of both culturally diverse patients and caregivers." - A-LIST Caregiver
What We’ve Learned: The Impact of COVID-19
of caregivers report having at least one stress symptom typically found in people experiencing severe stress.
of people with dementia report a decline in memory.
A-LIST in the News
Barron's: The Other Pandemic: What to Do About the Coming Alzheimer’s Crisis
The Latest A-LIST Publications
A-LIST Pulse of the Community, Volume 7, December 2020: Impacts of the Coronavirus Crisis on the Alzheimer’s Community
"Caregiver Perspectives on the Burden and Impact of Agitation in Caring for Loved Ones with Dementia/Alzheimer’s Disease," Clinical Trials on Alzheimer's Disease (CTAD) 2020.
UsA2 Voices of Alzheimer’s Program
Our vision is that rigorous data on what matters most to people living with dementia and care partners – the science of us – drives policy, research, drug development and access decisions affecting their lives. This program, which includes the A-LIST and AD PACE, develops patient and caregiver insights and experience data to inform advocacy, research, regulatory approvals, access determinations, care and services. This work will offer new knowledge to the field generally and advance drug development.